GSK plc reports 13 holdings worth about $497.0M in Q3 2026 13F
GSK plc 13F-HR for Q3 2026 reports 13 holdings totaling about $497.0M; routine institutional holdings disclosure.
What this filing says
GSK plc filed a quarterly Form 13F-HR listing 13 holdings with a combined reported value of $497,014,970 for the quarter ended September 30, 2026. The filing shows the drugmaker's own investment portfolio positions as of that date. It is a routine regulatory disclosure and does not by itself describe a change in strategy or any corporate event.
Key figures
- Number of holdings
- 13
- Reported holdings value
- $497,014,970
- Quarter ended
- September 30, 2026
- Filing date
- November 5, 2026
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- 13F-HR:
- A quarterly report that large institutional investment managers file with the SEC listing the equity securities they hold.
- Information table:
- The section of a 13F filing that itemizes each security held and its reported value.
FAQ
What does GSK plc's 13F filing report?
The filing reports 13 holdings with a total reported value of $497,014,970 as of September 30, 2026.
Does the filing include any other managers' holdings?
No, the filing lists no other included managers, so all reported holdings are GSK plc's own.
Historical context for GSK
Across the 26 sessions after earlier GSK headlines, the stock closed higher 10 times and lower 16 times, with a median move of 1.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GSK | SPY |
|---|---|---|---|
| Nov 4, 2026 | FDA Approval for BENLYSTA issued to GLAXOSMITHKLINE LLC | +5.0% | +1.7% |
| Nov 2, 2026 | Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026 | -0.8% | -0.5% |
| Oct 29, 2026 | GSK plc downgraded by Jefferies with a new price target | -0.1% | -0.4% |
| Oct 21, 2026 | Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) | -1.2% | +0.5% |
| Oct 20, 2026 | Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer | +2.4% | +0.3% |
| Oct 9, 2026 | Wolfe Research initiated coverage on GSK plc with a new price target | -0.1% | +0.6% |
Keep researching GSK
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Follow GSK and get a push notification the moment its next story breaks.